Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • biglabowski99 biglabowski99 Jan 21, 2013 6:34 PM Flag

    docihi asco gi

    Docihi will you be around tomorrow to review the esophageal and panc abstracts that are being released? I value your science interpretation.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • i will and hope to be helpful.

      • 1 Reply to docihi
      • eso - going nowhere and another indication that vis works on a limited list of cancers. pancreatic - the italian study was ok, but not overwhelming. we knew that vis is promising with stem cells in pancreatic adeno cancer. it is interesting that i have never heard another word that i can remember regarding vis and "cutting off the fuel supply" (glutamine). still nothing about vis/gem/abraxane in pancreatic; phii primary was due in december.

        this is of interest to me: "Abraxane/Gemcitabine Combination Improves Survival of Pancreatic Cancer Patients" (von hoff). we already knew that a nda was going to be submitted. of special interest is this line: " Significantly there was no increase in life-threatening toxicity. Other drug combinations that have demonstrated benefit have been limited by increased toxicities." does this mean the triple? maybe, maybe not.

 
CRIS
3.04-0.06(-1.94%)May 22 4:00 PMEDT